Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1558-1559, 2003; 10.1373/49.9.1558
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by den Hollander, J. G.
Right arrow Articles by Berghout, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by den Hollander, J. G.
Right arrow Articles by Berghout, A.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2003;49:1558-1559.)
© 2003 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Is Cystatin C a Marker of Glomerular Filtration Rate in Thyroid Dysfunction?

Jan G. den Hollander1, Raymond W. Wulkan2, Mart J. Mantel2 and Arie Berghout1,a

Departments of
1 Internal Medicine, and
2 Clinical Chemistry, Medical Center Rotterdam Zuid, Location Zuider, 3075 EA Rotterdam, The Netherlands

aAddress correspondence to this author at: Department of Internal Medicine, Medical Center Rijnmond Zuid, location Zuider, Groene Hilledijk 315, 3075 EA Rotterdam, The Netherlands. Fax 31-10-2903361; e-mail BerghoutA@MCRZ.nl.

The first 20% of the full text of this article appears below.

In the recent literature, cystatin C has been advocated as a new and more accurate estimate of glomerular filtration rate (GFR) (1). Cystatin C is a 13-kDa endogenous cysteine proteinase inhibitor produced by all nucleated cells at a constant rate and broken down completely in the renal tubuli (2). Cystatin C concentrations are independent of age and body weight, and there is no need for urine collection for clearance estimations. Furthermore, serum concentrations of cystatin C are not influenced by malignancy or inflammation. In contrast, the often-used serum creatinine concentration is supposedly influenced by dietary intake, renal tubular metabolism, age, and variations in muscle mass. There are also various analytical difficulties with the widely used Jaffe colorimetric assay for creatinine. A slight decrease in GFR has been found in patients with hypothyroidism, which improved significantly after treatment (3)(4)(5). We wondered whether cystatin C would also . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 NEJMHome page
A. Berghout, R. W. Wulkan, J. G. den Hollander, L. Risch, H. Drexel, A. R. Huber, B. A. Perkins, R. G. Nelson, A. S. Krolewski, M. G. Shlipak, et al.
Cystatin C and the risk of death.
N. Engl. J. Med., August 25, 2005; 353(8): 842 - 844.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.